Symbols / TAK Stock $16.65 +0.30% Takeda Pharmaceutical Company Limited
TAK (Stock) Chart
About
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Stock Fundamentals
Scroll to Statements| Market Cap | 52.60B | Enterprise Value | 4.79T | Income | 112.93B | Sales | 4.46T | Book/sh | 15.23 | Cash/sh | 414.62 |
| Dividend Yield | 3.98% | Payout | 279.05% | Employees | 47455 | IPO | — | P/E | 75.68 | Forward P/E | 31.42 |
| PEG | 0.36 | P/S | 0.01 | P/B | 1.09 | P/C | — | EV/EBITDA | 3.76 | EV/Sales | 1.07 |
| Quick Ratio | 0.54 | Current Ratio | 1.19 | Debt/Eq | 70.93 | LT Debt/Eq | — | EPS (ttm) | 0.22 | EPS next Y | 0.53 |
| EPS Growth | 3.30% | Revenue Growth | 4.20% | Earnings | 2026-05-13 | ROA | 2.47% | ROE | 1.50% | ROIC | — |
| Gross Margin | 65.53% | Oper. Margin | 10.85% | Profit Margin | 2.53% | Shs Outstand | 3.16B | Shs Float | 1.58B | Short Float | 0.22% |
| Short Ratio | 2.55 | Short Interest | — | 52W High | 18.90 | 52W Low | 12.99 | Beta | 0.13 | Avg Volume | 3.03M |
| Volume | 1.74M | Target Price | $20.40 | Recom | Strong_buy | Prev Close | $16.60 | Price | $16.65 | Change | 0.30% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-05-16 | main | TD Cowen | Outperform → Outperform | $20 |
| 2023-04-04 | main | TD Cowen | — → Outperform | $30 |
| 2023-03-16 | up | B of A Securities | Neutral → Buy | $20 |
| 2022-07-19 | up | Cowen & Co. | Market Perform → Outperform | $24 |
| 2021-10-07 | down | Morgan Stanley | Overweight → Equal-Weight | — |
| 2020-03-11 | main | JP Morgan | — → Overweight | $30 |
| 2019-11-01 | init | Cowen & Co. | — → Market Perform | $20 |
| 2019-09-24 | init | Jefferies | — → Buy | — |
News
RSS: Latest TAK news- SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally? - TradingView hu, 23 Apr 2026 16
- Bernstein Upgrades Takeda Pharmaceutical (TAK) to Outperform - Yahoo Finance Singapore hu, 23 Apr 2026 06
- Takeda Stock Stages Surprise Rebound After Steep Slide - TipRanks hu, 23 Apr 2026 09
- TAK Takeda Pharmaceutical Company Limited American Depositary Shares reports 90.6 percent Q1 2026 EPS beat, but stock slips slightly today. - Trending Stock Ideas - Xã Thanh Hà hu, 23 Apr 2026 04
- Takeda (TAK) Stock: Why It Could Change (Breakdown Watch) 2026-04-20 - Dividend Growth - Cổng thông tin điện tử Tỉnh Sơn La Mon, 20 Apr 2026 06
- Takeda Pharmaceutical Company L (TAK) Stock Analysis: Unlocking 15% Upside Potential - DirectorsTalk Interviews Mon, 20 Apr 2026 09
- Takeda (TAK) Resistance Levels | 90.6% EPS beat driven by robust pharma segment sales - Product Revenue - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 00
- Takeda (NYSE: TAK) CHRO discloses 71,836 ADS, 37,458 RSUs vesting through 2028 - Stock Titan Mon, 06 Apr 2026 07
- LTTS Share Price: Profit Badhane ke Liye Revenue Kam? Analysts Bole 'Hold' - Whalesbook hu, 23 Apr 2026 13
- (TAK) and the Role of Price-Sensitive Allocations - Stock Traders Daily Sun, 12 Apr 2026 20
- Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Yahoo Finance Sat, 31 Jan 2026 08
- Takeda Pharmaceutical Company L (TAK) Stock Analysis: A Closer Look at Its 3.58% Dividend Yield and Growth Potential - DirectorsTalk Interviews Mon, 16 Feb 2026 08
- FDA grants priority review to new injection for blood disorder polycythemia vera - Stock Titan Mon, 02 Mar 2026 08
- New Takeda pill targets root cause of rare sleep disorder - Stock Titan ue, 10 Feb 2026 08
- Takeda (NYSE: TAK) PDT unit president reports 84,787 ADS and RSU stake - Stock Titan Mon, 06 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
4,581,551.00
+7.45%
|
4,263,762.00
+5.87%
|
4,027,478.00
+12.85%
|
3,569,006.00
|
| Operating Revenue |
|
4,581,551.00
+7.45%
|
4,263,762.00
+5.87%
|
4,027,478.00
+12.85%
|
3,569,006.00
|
| Cost Of Revenue |
|
1,580,217.00
+10.76%
|
1,426,678.00
+14.68%
|
1,244,072.00
+12.40%
|
1,106,846.00
|
| Reconciled Cost Of Revenue |
|
1,462,054.00
+8.24%
|
1,350,793.00
+20.38%
|
1,122,115.00
+12.59%
|
996,610.00
|
| Gross Profit |
|
3,001,334.00
+5.79%
|
2,837,084.00
+1.93%
|
2,783,406.00
+13.05%
|
2,462,160.00
|
| Operating Expense |
|
2,515,273.00
+1.80%
|
2,470,919.00
+12.54%
|
2,195,594.00
+14.59%
|
1,916,117.00
|
| Research And Development |
|
730,227.00
+0.04%
|
729,924.00
+15.25%
|
633,325.00
+20.38%
|
526,087.00
|
| Selling General And Administration |
|
1,104,766.00
+4.83%
|
1,053,819.00
+5.67%
|
997,309.00
+12.52%
|
886,361.00
|
| Other Operating Expenses |
|
37,047.00
+5.67%
|
35,059.00
+55.70%
|
22,517.00
-26.78%
|
30,754.00
|
| Total Expenses |
|
4,095,490.00
+5.08%
|
3,897,597.00
+13.31%
|
3,439,666.00
+13.78%
|
3,022,963.00
|
| Operating Income |
|
486,061.00
+32.74%
|
366,165.00
-37.71%
|
587,812.00
+7.65%
|
546,043.00
|
| Total Operating Income As Reported |
|
342,586.00
+60.03%
|
214,075.00
-56.36%
|
490,505.00
+6.44%
|
460,844.00
|
| EBITDA |
|
1,073,791.00
+19.27%
|
900,328.00
-22.15%
|
1,156,463.00
+14.71%
|
1,008,154.00
|
| Normalized EBITDA |
|
1,239,111.00
+14.76%
|
1,079,710.00
-14.28%
|
1,259,585.00
+12.34%
|
1,121,266.00
|
| Reconciled Depreciation |
|
761,396.00
+4.59%
|
728,002.00
+9.57%
|
664,400.00
+13.93%
|
583,151.00
|
| EBIT |
|
312,395.00
+81.28%
|
172,326.00
-64.98%
|
492,063.00
+15.78%
|
425,003.00
|
| Total Unusual Items |
|
-165,320.00
+7.84%
|
-179,382.00
-73.95%
|
-103,122.00
+8.83%
|
-113,112.00
|
| Total Unusual Items Excluding Goodwill |
|
-165,320.00
+7.84%
|
-179,382.00
-73.95%
|
-103,122.00
+8.83%
|
-113,112.00
|
| Special Income Charges |
|
-172,923.00
-1.57%
|
-170,249.00
-55.39%
|
-109,562.00
-23.24%
|
-88,898.00
|
| Other Special Charges |
|
37,569.00
-40.72%
|
63,372.00
+157.52%
|
24,609.00
+565.47%
|
3,698.00
|
| Restructuring And Mergern Acquisition |
|
127,531.00
+24.89%
|
102,115.00
+61.51%
|
63,225.00
-12.96%
|
72,641.00
|
| Write Off |
|
18,384.00
+44.34%
|
12,737.00
-58.42%
|
30,629.00
+47.80%
|
20,723.00
|
| Net Income |
|
107,928.00
-25.08%
|
144,067.00
-54.56%
|
317,017.00
+37.80%
|
230,059.00
|
| Pretax Income |
|
175,084.00
+231.66%
|
52,791.00
-85.93%
|
375,090.00
+23.97%
|
302,571.00
|
| Net Non Operating Interest Income Expense |
|
-141,669.00
-0.86%
|
-140,463.00
-13.84%
|
-123,385.00
+0.07%
|
-123,477.00
|
| Interest Expense Non Operating |
|
137,311.00
+14.87%
|
119,535.00
+2.19%
|
116,973.00
-4.46%
|
122,432.00
|
| Net Interest Income |
|
—
|
—
|
-123,385.00
+0.07%
|
-123,477.00
|
| Interest Expense |
|
137,311.00
+14.87%
|
119,535.00
+2.19%
|
116,973.00
-4.46%
|
122,432.00
|
| Interest Income Non Operating |
|
19,638.00
+73.90%
|
11,293.00
+105.03%
|
5,508.00
+19.97%
|
4,591.00
|
| Interest Income |
|
19,638.00
+73.90%
|
11,293.00
+105.03%
|
5,508.00
+19.97%
|
4,591.00
|
| Other Income Expense |
|
-169,306.00
+2.08%
|
-172,909.00
-93.55%
|
-89,336.00
+25.55%
|
-119,997.00
|
| Gain On Sale Of Security |
|
7,603.00
+183.25%
|
-9,133.00
-241.82%
|
6,440.00
+126.60%
|
-24,214.00
|
| Gain On Sale Of Business |
|
10,198.00
+30.23%
|
7,831.00
+15.04%
|
6,807.00
-2.98%
|
7,016.00
|
| Tax Provision |
|
66,941.00
+173.23%
|
-91,406.00
-257.46%
|
58,052.00
-19.82%
|
72,405.00
|
| Tax Rate For Calcs |
|
0.00
+64.80%
|
0.00
+49.90%
|
0.00
-35.32%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-63,207.87
-51.88%
|
-41,616.62
-160.76%
|
-15,960.01
+41.04%
|
-27,067.61
|
| Net Income Including Noncontrolling Interests |
|
108,143.00
-25.00%
|
144,197.00
-54.52%
|
317,038.00
+37.74%
|
230,166.00
|
| Net Income From Continuing Operation Net Minority Interest |
|
107,928.00
-25.08%
|
144,067.00
-54.56%
|
317,017.00
+37.80%
|
230,059.00
|
| Net Income From Continuing And Discontinued Operation |
|
107,928.00
-25.08%
|
144,067.00
-54.56%
|
317,017.00
+37.80%
|
230,059.00
|
| Net Income Continuous Operations |
|
108,143.00
-25.00%
|
144,197.00
-54.52%
|
317,038.00
+37.74%
|
230,166.00
|
| Minority Interests |
|
-215.00
-65.38%
|
-130.00
-519.05%
|
-21.00
+80.37%
|
-107.00
|
| Normalized Income |
|
210,040.13
-25.47%
|
281,832.38
-30.27%
|
404,178.99
+27.86%
|
316,103.39
|
| Net Income Common Stockholders |
|
107,928.00
-25.08%
|
144,067.00
-54.56%
|
317,017.00
+37.80%
|
230,059.00
|
| Diluted EPS |
|
33.62
-26.25%
|
45.58
-54.86%
|
100.97
+38.44%
|
72.94
|
| Basic EPS |
|
34.18
-25.77%
|
46.05
-54.92%
|
102.14
+38.84%
|
73.57
|
| Basic Average Shares |
|
3,157.75
+0.92%
|
3,128.90
+0.81%
|
3,103.62
-0.75%
|
3,127.00
|
| Diluted Average Shares |
|
3,210.65
+1.58%
|
3,160.69
+0.67%
|
3,139.74
-0.46%
|
3,154.34
|
| Diluted NI Availto Com Stockholders |
|
107,928.00
-25.08%
|
144,067.00
-54.56%
|
317,017.00
+37.80%
|
230,059.00
|
| Amortization |
|
643,233.00
-1.36%
|
652,117.00
+20.22%
|
542,443.00
+14.70%
|
472,915.00
|
| Amortization Of Intangibles Income Statement |
|
643,233.00
-1.36%
|
652,117.00
+20.22%
|
542,443.00
+14.70%
|
472,915.00
|
| Depreciation Amortization Depletion Income Statement |
|
643,233.00
-1.36%
|
652,117.00
+20.22%
|
542,443.00
+14.70%
|
472,915.00
|
| Depreciation And Amortization In Income Statement |
|
643,233.00
-1.36%
|
652,117.00
+20.22%
|
542,443.00
+14.70%
|
472,915.00
|
| Earnings From Equity Interest |
|
-3,986.00
-161.58%
|
6,473.00
-53.05%
|
13,786.00
+300.23%
|
-6,885.00
|
| Gain On Sale Of PPE |
|
363.00
+152.08%
|
144.00
-93.12%
|
2,094.00
+82.40%
|
1,148.00
|
| Total Other Finance Cost |
|
23,996.00
-25.53%
|
32,221.00
+170.31%
|
11,920.00
+111.50%
|
5,636.00
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets |
|
14,248,344.00
-5.70%
|
15,108,792.00
+8.25%
|
13,957,750.00
+5.92%
|
13,178,018.00
|
| Current Assets |
|
2,521,192.00
-1.46%
|
2,558,580.00
+6.70%
|
2,397,956.00
-7.54%
|
2,593,642.00
|
| Cash Cash Equivalents And Short Term Investments |
|
405,589.00
-14.23%
|
472,889.00
-14.60%
|
553,704.00
-36.72%
|
875,000.00
|
| Cash And Cash Equivalents |
|
385,113.00
-15.88%
|
457,800.00
-14.19%
|
533,530.00
-37.21%
|
849,695.00
|
| Cash Equivalents |
|
151,371.00
-40.08%
|
252,611.00
-16.90%
|
303,973.00
-34.01%
|
460,637.00
|
| Cash Financial |
|
233,742.00
+13.91%
|
205,190.00
-10.61%
|
229,557.00
-41.00%
|
389,059.00
|
| Other Short Term Investments |
|
20,476.00
+35.70%
|
15,089.00
-25.21%
|
20,174.00
-20.28%
|
25,305.00
|
| Receivables |
|
725,254.00
+3.96%
|
697,610.00
+2.33%
|
681,694.00
-5.89%
|
724,378.00
|
| Accounts Receivable |
|
770,896.00
+7.27%
|
718,675.00
+6.52%
|
674,691.00
-5.01%
|
710,304.00
|
| Receivables Adjustments Allowances |
|
-119,481.00
-12.47%
|
-106,236.00
-7.03%
|
-99,260.00
-6.98%
|
-92,786.00
|
| Other Receivables |
|
58,050.00
+3.73%
|
55,964.00
-24.37%
|
73,999.00
-6.48%
|
79,127.00
|
| Taxes Receivable |
|
15,789.00
-45.94%
|
29,207.00
-9.47%
|
32,264.00
+16.34%
|
27,733.00
|
| Inventory |
|
1,217,349.00
+0.62%
|
1,209,869.00
+22.65%
|
986,457.00
+15.62%
|
853,167.00
|
| Raw Materials |
|
341,636.00
+1.19%
|
337,612.00
+20.19%
|
280,908.00
+24.86%
|
224,977.00
|
| Work In Process |
|
552,200.00
+5.65%
|
522,667.00
+19.74%
|
436,508.00
+8.02%
|
404,087.00
|
| Finished Goods |
|
323,513.00
-7.46%
|
349,590.00
+29.94%
|
269,042.00
+20.05%
|
224,102.00
|
| Assets Held For Sale Current |
|
13,397.00
+43.48%
|
9,337.00
-38.71%
|
15,235.00
|
0.00
|
| Other Current Assets |
|
159,603.00
-5.49%
|
168,875.00
+4.98%
|
160,866.00
+14.01%
|
141,097.00
|
| Total Non Current Assets |
|
11,727,152.00
-6.56%
|
12,550,214.00
+8.57%
|
11,559,794.00
+9.22%
|
10,584,377.00
|
| Net PPE |
|
1,968,209.00
-1.08%
|
1,989,777.00
+17.65%
|
1,691,229.00
+6.85%
|
1,582,800.00
|
| Gross PPE |
|
3,273,239.00
+1.95%
|
3,210,478.00
+18.95%
|
2,698,983.00
+10.03%
|
2,453,008.00
|
| Accumulated Depreciation |
|
-1,305,030.00
-6.91%
|
-1,220,701.00
-21.13%
|
-1,007,754.00
-15.81%
|
-870,208.00
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
104,342.00
-1.42%
|
105,845.00
+7.76%
|
98,227.00
-0.43%
|
98,654.00
|
| Buildings And Improvements |
|
1,671,876.00
-0.43%
|
1,679,054.00
+19.92%
|
1,400,108.00
+8.66%
|
1,288,578.00
|
| Machinery Furniture Equipment |
|
1,175,365.00
+2.48%
|
1,146,889.00
+15.47%
|
993,249.00
+9.40%
|
907,919.00
|
| Construction In Progress |
|
321,656.00
+15.42%
|
278,689.00
+34.37%
|
207,400.00
+31.39%
|
157,856.00
|
| Goodwill And Other Intangible Assets |
|
8,955,990.00
-7.52%
|
9,684,750.00
+6.89%
|
9,060,380.00
+10.14%
|
8,226,294.00
|
| Goodwill |
|
5,324,430.00
-1.58%
|
5,410,067.00
+12.93%
|
4,790,723.00
+8.69%
|
4,407,749.00
|
| Other Intangible Assets |
|
3,631,560.00
-15.04%
|
4,274,683.00
+0.12%
|
4,269,657.00
+11.81%
|
3,818,545.00
|
| Investments And Advances |
|
361,926.00
-15.95%
|
430,608.00
+13.66%
|
378,857.00
+14.76%
|
330,133.00
|
| Long Term Equity Investment |
|
10,802.00
-87.98%
|
89,831.00
-9.42%
|
99,174.00
+2.69%
|
96,579.00
|
| Non Current Deferred Assets |
|
370,745.00
-5.87%
|
393,865.00
+7.61%
|
366,003.00
+0.96%
|
362,539.00
|
| Non Current Deferred Taxes Assets |
|
370,745.00
-5.87%
|
393,865.00
+7.61%
|
366,003.00
+0.96%
|
362,539.00
|
| Other Non Current Assets |
|
70,282.00
+37.23%
|
51,214.00
-19.13%
|
63,325.00
-23.35%
|
82,611.00
|
| Total Liabilities Net Minority Interest |
|
7,312,365.00
-6.67%
|
7,834,787.00
+3.05%
|
7,603,079.00
+1.45%
|
7,494,495.00
|
| Current Liabilities |
|
2,506,521.00
+8.36%
|
2,313,103.00
-6.80%
|
2,481,940.00
+15.67%
|
2,145,730.00
|
| Payables And Accrued Expenses |
|
609,038.00
-7.36%
|
657,427.00
-25.43%
|
881,610.00
+22.92%
|
717,216.00
|
| Payables |
|
609,038.00
-7.36%
|
657,427.00
-25.43%
|
881,610.00
+22.92%
|
717,216.00
|
| Accounts Payable |
|
308,450.00
-3.60%
|
319,955.00
+4.07%
|
307,453.00
+3.89%
|
295,934.00
|
| Other Payable |
|
167,091.00
-26.57%
|
227,566.00
-33.42%
|
341,780.00
+55.10%
|
220,364.00
|
| Employee Benefits |
|
135,429.00
-5.87%
|
143,882.00
+12.77%
|
127,594.00
-12.52%
|
145,847.00
|
| Total Tax Payable |
|
133,497.00
+21.46%
|
109,906.00
-52.70%
|
232,377.00
+15.66%
|
200,918.00
|
| Income Tax Payable |
|
133,497.00
+21.46%
|
109,906.00
-52.70%
|
232,377.00
+15.66%
|
200,918.00
|
| Current Debt And Capital Lease Obligation |
|
548,939.00
+49.47%
|
367,251.00
+8.14%
|
339,600.00
+66.48%
|
203,993.00
|
| Current Debt |
|
548,939.00
+49.47%
|
367,251.00
+8.14%
|
339,600.00
+66.48%
|
203,993.00
|
| Other Current Borrowings |
|
548,939.00
+49.47%
|
367,251.00
+8.14%
|
339,600.00
+66.48%
|
203,993.00
|
| Other Current Liabilities |
|
815,404.00
+6.73%
|
764,005.00
+1.55%
|
752,370.00
-3.67%
|
781,019.00
|
| Total Non Current Liabilities Net Minority Interest |
|
4,805,844.00
-12.96%
|
5,521,684.00
+7.82%
|
5,121,139.00
-4.26%
|
5,348,765.00
|
| Long Term Debt And Capital Lease Obligation |
|
3,966,326.00
-11.40%
|
4,476,501.00
+10.73%
|
4,042,741.00
-2.38%
|
4,141,418.00
|
| Long Term Debt |
|
3,966,326.00
-11.40%
|
4,476,501.00
+10.73%
|
4,042,741.00
-2.38%
|
4,141,418.00
|
| Long Term Provisions |
|
35,177.00
+144.74%
|
14,373.00
-74.32%
|
55,969.00
+7.22%
|
52,199.00
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
135,429.00
-5.87%
|
143,882.00
+12.77%
|
127,594.00
-12.52%
|
145,847.00
|
| Tradeand Other Payables Non Current |
|
317.00
-92.76%
|
4,381.00
-82.16%
|
24,558.00
+13.52%
|
21,634.00
|
| Non Current Deferred Liabilities |
|
35,153.00
-69.10%
|
113,777.00
-57.96%
|
270,620.00
-40.06%
|
451,511.00
|
| Non Current Deferred Taxes Liabilities |
|
35,153.00
-69.10%
|
113,777.00
-57.96%
|
270,620.00
-40.06%
|
451,511.00
|
| Other Non Current Liabilities |
|
633,442.00
-17.60%
|
768,770.00
+28.20%
|
599,657.00
+11.84%
|
536,156.00
|
| Stockholders Equity |
|
6,935,084.00
-4.65%
|
7,273,264.00
+14.47%
|
6,354,122.00
+11.81%
|
5,683,019.00
|
| Common Stock Equity |
|
6,935,084.00
-4.65%
|
7,273,264.00
+14.47%
|
6,354,122.00
+11.81%
|
5,683,019.00
|
| Capital Stock |
|
1,694,685.00
+1.08%
|
1,676,596.00
+0.01%
|
1,676,345.00
+0.00%
|
1,676,263.00
|
| Common Stock |
|
1,694,685.00
+1.08%
|
1,676,596.00
+0.01%
|
1,676,345.00
+0.00%
|
1,676,263.00
|
| Share Issued |
|
1,590.95
+0.54%
|
1,582.42
+0.01%
|
1,582.30
+0.00%
|
1,582.25
|
| Ordinary Shares Number |
|
1,573.65
+0.30%
|
1,569.01
+0.93%
|
1,554.53
-0.33%
|
1,559.61
|
| Treasury Shares Number |
|
17.30
+29.05%
|
13.41
-51.72%
|
27.77
+22.61%
|
22.65
|
| Additional Paid In Capital |
|
1,775,713.00
+1.62%
|
1,747,414.00
+1.07%
|
1,728,830.00
+1.17%
|
1,708,873.00
|
| Retained Earnings |
|
1,187,586.00
-14.64%
|
1,391,203.00
-9.73%
|
1,541,146.00
+4.15%
|
1,479,716.00
|
| Treasury Stock |
|
74,815.00
+45.95%
|
51,259.00
-48.90%
|
100,317.00
-13.53%
|
116,007.00
|
| Minority Interest |
|
895.00
+20.78%
|
741.00
+34.97%
|
549.00
+8.93%
|
504.00
|
| Total Equity Gross Minority Interest |
|
6,935,979.00
-4.65%
|
7,274,005.00
+14.47%
|
6,354,671.00
+11.81%
|
5,683,523.00
|
| Total Capitalization |
|
10,901,410.00
-7.22%
|
11,749,765.00
+13.01%
|
10,396,863.00
+5.83%
|
9,824,437.00
|
| Working Capital |
|
14,671.00
-94.02%
|
245,477.00
+392.29%
|
-83,984.00
-118.75%
|
447,912.00
|
| Invested Capital |
|
11,450,349.00
-5.50%
|
12,117,016.00
+12.86%
|
10,736,463.00
+7.06%
|
10,028,430.00
|
| Total Debt |
|
4,515,265.00
-6.78%
|
4,843,752.00
+10.53%
|
4,382,341.00
+0.85%
|
4,345,411.00
|
| Net Debt |
|
4,130,152.00
-5.83%
|
4,385,952.00
+13.96%
|
3,848,811.00
+10.10%
|
3,495,716.00
|
| Net Tangible Assets |
|
-2,020,906.00
+16.20%
|
-2,411,486.00
+10.89%
|
-2,706,258.00
-6.41%
|
-2,543,275.00
|
| Tangible Book Value |
|
-2,020,906.00
+16.20%
|
-2,411,486.00
+10.89%
|
-2,706,258.00
-6.41%
|
-2,543,275.00
|
| Available For Sale Securities |
|
351,124.00
+3.04%
|
340,777.00
+21.84%
|
279,683.00
+19.75%
|
233,554.00
|
| Current Provisions |
|
533,140.00
+1.66%
|
524,420.00
+3.16%
|
508,360.00
+14.62%
|
443,502.00
|
| Investmentin Financial Assets |
|
351,124.00
+3.04%
|
340,777.00
+21.84%
|
279,683.00
+19.75%
|
233,554.00
|
| Other Equity Interest |
|
2,351,915.00
-6.27%
|
2,509,310.00
+66.39%
|
1,508,118.00
+61.44%
|
934,174.00
|
| Other Inventories |
|
—
|
—
|
-1.00
-200.00%
|
1.00
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
1,057,182.00
+47.58%
|
716,344.00
-26.69%
|
977,156.00
-13.00%
|
1,123,105.00
|
| Cash Flow From Continuing Operating Activities |
|
1,057,181.00
+47.58%
|
716,344.00
-26.69%
|
977,157.00
-13.00%
|
1,123,107.00
|
| Net Income From Continuing Operations |
|
108,143.00
-25.00%
|
144,197.00
-54.52%
|
317,038.00
+37.74%
|
230,166.00
|
| Depreciation Amortization Depletion |
|
761,396.00
+4.59%
|
728,002.00
+9.57%
|
664,400.00
+13.93%
|
583,151.00
|
| Depreciation And Amortization |
|
761,396.00
+4.59%
|
728,002.00
+9.57%
|
664,400.00
+13.93%
|
583,151.00
|
| Other Non Cash Items |
|
153,410.00
-4.24%
|
160,201.00
+789.71%
|
18,006.00
-90.23%
|
184,314.00
|
| Stock Based Compensation |
|
72,867.00
+2.82%
|
70,871.00
+16.81%
|
60,672.00
+39.88%
|
43,374.00
|
| Asset Impairment Charge |
|
106,529.00
-28.99%
|
150,017.00
+132.97%
|
64,394.00
+18.12%
|
54,515.00
|
| Deferred Tax |
|
66,941.00
+173.23%
|
-91,406.00
-257.46%
|
58,052.00
-19.82%
|
72,405.00
|
| Deferred Income Tax |
|
66,941.00
+173.23%
|
-91,406.00
-257.46%
|
58,052.00
-19.82%
|
72,405.00
|
| Operating Gains Losses |
|
-1,717.00
+79.20%
|
-8,253.00
-550.25%
|
1,833.00
-77.63%
|
8,193.00
|
| Unrealized Gain Loss On Investment Securities |
|
-602.00
-102.90%
|
20,757.00
+420.10%
|
3,991.00
+135.65%
|
-11,195.00
|
| Gain Loss On Sale Of PPE |
|
4,495.00
-25.73%
|
6,052.00
+60420.00%
|
10.00
-98.47%
|
655.00
|
| Change In Working Capital |
|
-59,372.00
+76.81%
|
-256,003.00
-913.31%
|
-25,264.00
-125.62%
|
98,605.00
|
| Change In Receivables |
|
-58,959.00
-490.35%
|
15,104.00
-79.90%
|
75,127.00
-40.98%
|
127,294.00
|
| Change In Inventory |
|
-34,973.00
+69.78%
|
-115,743.00
-46.22%
|
-79,155.00
-71.52%
|
-46,148.00
|
| Change In Payables And Accrued Expense |
|
-7,118.00
+28.06%
|
-9,895.00
+88.33%
|
-84,804.00
-167.76%
|
125,157.00
|
| Change In Payable |
|
-7,118.00
+28.06%
|
-9,895.00
+88.33%
|
-84,804.00
-167.76%
|
125,157.00
|
| Change In Other Working Capital |
|
45,166.00
+135.59%
|
-126,901.00
-497.82%
|
31,899.00
+154.91%
|
-58,090.00
|
| Change In Other Current Liabilities |
|
-3,488.00
+81.21%
|
-18,568.00
-158.63%
|
31,669.00
+163.84%
|
-49,608.00
|
| Investing Cash Flow |
|
-367,060.00
+20.87%
|
-463,862.00
+23.59%
|
-607,102.00
-206.42%
|
-198,125.00
|
| Cash Flow From Continuing Investing Activities |
|
-367,061.00
+20.87%
|
-463,861.00
+23.59%
|
-607,102.00
-206.42%
|
-198,126.00
|
| Net PPE Purchase And Sale |
|
-200,717.00
-20.32%
|
-166,814.00
-19.41%
|
-139,695.00
-15.03%
|
-121,437.00
|
| Purchase Of PPE |
|
-200,795.00
-14.47%
|
-175,420.00
-24.71%
|
-140,657.00
-14.12%
|
-123,252.00
|
| Sale Of PPE |
|
78.00
-99.09%
|
8,606.00
+794.59%
|
962.00
-47.00%
|
1,815.00
|
| Capital Expenditure |
|
-379,625.00
+21.03%
|
-480,730.00
+24.14%
|
-633,689.00
-240.63%
|
-186,037.00
|
| Net Investment Purchase And Sale |
|
-81,941.00
-155.71%
|
-32,045.00
-364.77%
|
12,103.00
+41.06%
|
8,580.00
|
| Purchase Of Investment |
|
-111,383.00
-178.00%
|
-40,066.00
-294.70%
|
-10,151.00
-21.70%
|
-8,341.00
|
| Sale Of Investment |
|
29,442.00
+267.06%
|
8,021.00
-63.96%
|
22,254.00
+31.52%
|
16,921.00
|
| Net Business Purchase And Sale |
|
77,243.00
+287.01%
|
19,959.00
+150.80%
|
7,958.00
+137.06%
|
-21,476.00
|
| Purchase Of Business |
|
-1,004.00
|
0.00
|
0.00
+100.00%
|
-49,672.00
|
| Gain Loss On Sale Of Business |
|
-10,198.00
-30.21%
|
-7,832.00
-15.06%
|
-6,807.00
+13.05%
|
-7,829.00
|
| Net Intangibles Purchase And Sale |
|
-178,830.00
+41.43%
|
-305,310.00
+38.08%
|
-493,032.00
-685.27%
|
-62,785.00
|
| Purchase Of Intangibles |
|
-178,830.00
+41.43%
|
-305,310.00
+38.08%
|
-493,032.00
-685.27%
|
-62,785.00
|
| Net Other Investing Changes |
|
-1,110.00
+72.28%
|
-4,004.00
-31.19%
|
-3,052.00
+58.35%
|
-7,327.00
|
| Financing Cash Flow |
|
-751,425.00
-112.02%
|
-354,416.00
+50.02%
|
-709,148.00
+33.74%
|
-1,070,265.00
|
| Cash Flow From Continuing Financing Activities |
|
-751,423.00
-112.02%
|
-354,415.00
+50.02%
|
-709,149.00
+33.74%
|
-1,070,265.00
|
| Net Issuance Payments Of Debt |
|
-314,314.00
-20874.22%
|
1,513.00
+100.53%
|
-285,071.00
+52.53%
|
-600,477.00
|
| Issuance Of Debt |
|
1,051,950.00
+179.03%
|
377,000.00
+227.83%
|
115,000.00
-53.88%
|
249,334.00
|
| Repayment Of Debt |
|
-1,366,264.00
-263.86%
|
-375,487.00
+6.14%
|
-400,071.00
+52.92%
|
-849,809.00
|
| Long Term Debt Issuance |
|
1,024,460.00
+924.46%
|
100,000.00
+33.33%
|
75,000.00
-69.92%
|
249,334.00
|
| Long Term Debt Payments |
|
-1,366,264.00
-263.86%
|
-375,487.00
+6.14%
|
-400,071.00
+52.92%
|
-849,809.00
|
| Net Long Term Debt Issuance |
|
-341,804.00
-24.07%
|
-275,487.00
+15.25%
|
-325,071.00
+45.86%
|
-600,475.00
|
| Short Term Debt Issuance |
|
27,490.00
-90.08%
|
277,000.00
+592.50%
|
40,000.00
|
—
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
-2.00
|
| Net Short Term Debt Issuance |
|
27,490.00
-90.08%
|
277,000.00
+592.50%
|
40,000.00
+2000100.00%
|
-2.00
|
| Net Common Stock Issuance |
|
-51,860.00
-2129.58%
|
-2,326.00
+91.36%
|
-26,929.00
+65.27%
|
-77,531.00
|
| Common Stock Payments |
|
-51,860.00
-2129.58%
|
-2,326.00
+91.36%
|
-26,929.00
+65.27%
|
-77,531.00
|
| Common Stock Dividend Paid |
|
—
|
—
|
-279,416.00
+1.50%
|
-283,665.00
|
| Cash Dividends Paid |
|
-302,498.00
-5.33%
|
-287,188.00
-2.78%
|
-279,416.00
+1.50%
|
-283,665.00
|
| Repurchase Of Capital Stock |
|
-51,860.00
-2129.58%
|
-2,326.00
+91.36%
|
-26,929.00
+65.27%
|
-77,531.00
|
| Net Other Financing Charges |
|
30,231.00
-10.98%
|
33,960.00
+470.06%
|
-9,177.00
-2283.64%
|
-385.00
|
| Changes In Cash |
|
-61,302.00
+39.86%
|
-101,934.00
+69.94%
|
-339,094.00
-133.40%
|
-145,285.00
|
| Effect Of Exchange Rate Changes |
|
-11,385.00
-143.45%
|
26,204.00
+14.28%
|
22,929.00
-20.27%
|
28,758.00
|
| Beginning Cash Position |
|
457,800.00
-14.19%
|
533,530.00
-37.21%
|
849,695.00
-12.06%
|
966,222.00
|
| End Cash Position |
|
385,113.00
-15.88%
|
457,800.00
-14.19%
|
533,530.00
-37.21%
|
849,695.00
|
| Free Cash Flow |
|
677,557.00
+187.57%
|
235,614.00
-31.40%
|
343,467.00
-63.35%
|
937,068.00
|
| Dividends Received CFI |
|
635.00
-95.19%
|
13,191.00
+270.33%
|
3,562.00
+4.73%
|
3,401.00
|
| Earnings Losses From Equity Investments |
|
3,986.00
+161.58%
|
-6,473.00
-175.01%
|
8,630.00
-43.84%
|
15,367.00
|
| Interest Paid CFF |
|
-112,984.00
-12.56%
|
-100,375.00
+7.54%
|
-108,555.00
-0.32%
|
-108,207.00
|
| Interest Received CFI |
|
17,660.00
+58.23%
|
11,161.00
+120.83%
|
5,054.00
+73.14%
|
2,919.00
|
| Sale Of Business |
|
78,247.00
+292.04%
|
19,959.00
+150.80%
|
7,958.00
-71.78%
|
28,196.00
|
| Taxes Refund Paid |
|
-150,413.00
+25.55%
|
-202,039.00
-8.64%
|
-185,966.00
-32.43%
|
-140,423.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42025-12-09 View
- 42025-09-19 View
- 42024-01-25 View
- 42023-05-26 View
- 42022-12-01 View
- 42022-07-06 View
- 42022-07-06 View
- 42022-03-16 View
- 42021-12-09 View
- 42021-12-07 View
- 42021-11-29 View
- 42021-11-08 View
- 42021-10-26 View
- 42021-10-15 View
- 42021-07-09 View
- 42021-07-06 View
- 42021-06-29 View
- 42021-06-25 View
- 42021-06-23 View
- 42021-06-21 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|